Korean biotech ventures have been unveiling a string of new clinical trial approvals and interim results in Australia this year, drawing attention to the country's appeal. Experts attribute the trend to Australia's clinical trial-friendly environment, including tax incentives and access to multi-ethnic data, which has made it a consistent choice as an early-stage clinical hub.
According to the Financial Supervisory Service's electronic disclosure system on Tuesday, Inventage Lab recently disclosed the results of an Australian Phase 1 trial for its Alzheimer's disease treatment "IVL3003." In February, the company also obtained Investigational New Drug (IND) approval for a Phase 2 trial from Australia's Human Research Ethics Committee (HREC) for "IVL3001," a long-acting hair loss treatment being co-developed with Daewoong Pharmaceutical.
GI Innovation also received Australian Phase 1/2 IND approval in February for its immuno-oncology candidate "GI-102." The same month, Voronoi disclosed Australian Phase 1 IND approval for "VRN110755," targeting non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations, establishing a multinational clinical trial framework spanning Korea, Taiwan and Hong Kong.
Biosolution also received Australian Phase 1/2 IND approval for its allogeneic chondrocyte therapy "Cartiroid," with trials planned at three institutions in total.
Tax incentives and access to multi-ethnic data are cited as key reasons biotech firms are choosing Australia as a forward base for global clinical trials. Australia operates a program that refunds up to 38.5% to 43.5% of research and development (R&D) costs depending on company revenue size. This allows cash-strapped early-stage biotech ventures to recoup nearly half of their clinical trial expenses.
Australia also offers advantages in securing clinical data. As a multi-ethnic society comprising Caucasians, Blacks, Asians and Hispanics, Australia makes "bridging studies," which select specific ethnic groups for trials, relatively easy to conduct. Data obtained in this way carries high credibility with major regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), making expansion into global clinical trials relatively straightforward. Typically, early-stage trials conducted in Korea require repeating Phases 1 and 2 for U.S. market entry, but trials conducted in Australia reportedly qualify for direct advancement to Phase 3 in the United States.
"Australia continues to build national-level clinical infrastructure, including refunding a significant portion of investment when companies establish local entities," said Chung Yoon-taek, head of the Pharmaceutical Industry Strategy Institute. In fact, Pharos iBio recently announced it would dissolve its U.S. subsidiary and restructure operations around its Australian entity to improve clinical trial efficiency.
"New drug developers take a long time to generate revenue, and Australia essentially offers a 'payback' structure for R&D costs," an industry official said. "Biotech ventures short on cash have no choice but to flock to Australia."
